1. Introduction {#sec1}
===============

Polyphenols are the largest group of phytochemicals, secondary metabolites of plant produce to protect themselves from insects, mushrooms and diseases ([@bib27]); classified as flavones, flavonols, phenolic acids, volatile phenols, anthocyanins, catechins and tannins ([@bib20]). They have received tremendous attention among nutritionists, food scientists and consumers due to their roles in human health. Research in the recent years strongly supports their role in the prevention of the diseases, particularly cancer, cardiovascular diseases, diabetes and neurodegenerative disorders ([@bib18]).

Syringic acid (SA) is one of the examples of phenolic acid found in various dry fruits (olives, dates), spices, pumpkin, grapes, acai palm, honey, red wine and other plants ([@bib31]). SA exhibits diverse pharmacological actions such as antidiabetic ([@bib16]), antibacterial ([@bib4]). It inhibits aldose reductase enzyme ([@bib38]), showed antioxidant and antihypertensive ([@bib22]), hepatoprotective ([@bib26]) and neuroprotective activity ([@bib35]). It has antiglycating properties ([@bib1]), anti-steatotic and anti-inflammatory effect ([@bib17]) and have improved diabetic cataract ([@bib38]). Additionally, it has been proven to have anti-cancer property, protects the heart and brain/CNS, employed in the preparation of dental cement ([@bib31]), attenuates clot formation and acute thromboembolism in mice ([@bib7]).

SA is supposed to be administered to treat chronic disorders for a long period; therefore an evaluation of safety becomes essential. In addition, current scientific reports showed toxic effects of phytochemicals or plant extracts in experimental animals at high doses such as carcinogenic (capsaicin*,* chili powder, safrole), neurotoxic (*Papaver somniferum, erytroxylum sp.* and *cannabis sativa*), genotoxic (thymol and carvacro), teratogenic (pyrrolizidine alkaloid monster, heliotrine), cytotoxic (*Allium sativum*, *Lagerstroemia speciosa*, *Calotropisprocera, Chenopodiummurale, Pulicariaorientalis, Tribulusterrestris, Withania somniferum*, *Blumealacera* and safrole-2′, 3′-oxide), nephrotoxic (aristolochic acid*,* turmeric*,* Juniper berries, green tea-derived preparations, Teavigo, Polyphenon E), hepatotoxic (*Cimicifugaracemosa,* Herbalifeproducts), and gastrointestinal effects (myristicin, elemicin, omum/ajwain, red pepper, fennel, cardamom, dark pepper, cumin, coriander and ginger) ([@bib13]). [@bib6] documented case studies of twenty one herbs and twelve dietary supplements which posed a possible risk for liver injuries. In certain individuals, herbs with the high number of published reports (but not cases studies) were germander, black cohosh, kava extract, and green tea extract.

These reports are alarming and showed that there is a need of creating awareness, particularly amongst clinicians and patients for usage of safe phytochemical dose. At the same time, it compels researchers to evaluate safety of phytochemicals. Research in the toxicological domain (such as acute, subacute, subchronic and chronic studies) not only adds value to the ethanopharmacology of phytochemicals but also it will ensure the safe use and may avoid the occurrence of any untoward effects which were considered to be a major obstacle with the synthetic drugs. As per the OECD TG 407 ([@bib34]), subacute toxicity studies are usually carried out after the availability of initial information on acute toxicity studies. It provides information on possible health hazards likely to arise from repeated exposure of drugs/chemical over a limited period of time ([@bib15]) and also, it helps in establishing-doses-for the longer-term subchronic studies ([@bib9]). In addition, subacute toxicology studies in rodents are considered to be an obligatory step to support the progression to clinical trials and the eventual marketing of drug molecules ([@bib11]).

However, to the best of our knowledge, no reports of subacute toxicity of SA are available in the literature. Hence, it was decided to conduct a subacute toxicity study. The objective was to find out safety aspects of SA on vital internal body organs (such as liver, brain, heart, kidney and sciatic nerve) in Wistar rats. This study will add value to its ethanopharmacological profile; provide preliminary data for researchers to conduct long-term toxicity studies (subchronic and chronic studies). Further, provide a platform to search ways of decreasing its toxic effects (if any).

2. Material and methods {#sec2}
=======================

2.1. Chemicals {#sec2.1}
--------------

Syringic acid (HSN-98020000) was purchased from TCI Chemicals (Tokyo, Japan) with 97% purity and sodium chloride solution (0.9 % w/v) was purchased from Aculife Healthcare Pvt. Ltd. (Gujrat, India) through local supplier. The SA was dissolved in sterile, non-pyrogenic sodium chloride solution (0.9 % w/v) on a daily basis in aseptic condition. World Health Organization has included sodium chloride solution (0.9 % w/v) in the List of Essential Medicines and considered it as an effective and safe medicine for the health system. All required biochemical kits were of analytical grade and purchased from the Lab-Care Diagnostics Pvt Ltd and Transasia Bio-Medicals Ltd, India.

2.2. Experimental animals {#sec2.2}
-------------------------

Healthy young adult male and female Wistar albino rats were obtained from the National Institute of Bioscience, Pune. The basic animal feed was provided by Nutrivet Life Sciences, Pune (57 % carbohydrate, 20 % protein, 4 % fat, 4.3 % fiber).

They were housed under standard environmental conditions of temperature at 22 ± 1 °C under a 12 h-light: 12 h-dark cycle (8.00 am--20.00 pm). Male and female rats were housed separately in sterile polypropylene cages. Fed with basic feed and purified water, allowed free access to drinking water and standard pelleted diet. All rats were allowed to adapt to the new environment for one week before the study.

2.3. Ethical approval {#sec2.3}
---------------------

The experimental design of the present study was reviewed and approved with reference no. AIKTC/SOP/IAEC/2017/03 by the Institutional Animal Ethical Committee of AI\'s Kalsekar Technical Campus (AIKTC), Mumbai, Maharashtra, India (Reg.No.1771/PO/Re/S/14/CPCSEA) and animals were maintained as per the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), India.

2.4. Limit test/dose selection assay {#sec2.4}
------------------------------------

As per [@bib12], initially a single dose of SA (2000 mg/kg b.w) was orally administered to 1 rat and then based on observation of mortality and morbidity, the SA (2000 mg/kg b.w) was administered to another 4 rats. All the rats were observed critically for any mortality and toxic signs for 14 days. The limit test was performed to determine the LD50 value and the dose for subacute toxicity study.

2.5. Subacute toxicity {#sec2.5}
----------------------

According to OECD TG 407 ([@bib34]), 36 rats (18 male and 18 female) were randomized into 3 groups having 12 rats each group (n = 12). The rats were marked to permit individual identification. Male and female rats were kept in separate cages and cages were numbered. Rats groups were as follows.i.**Control group** \[1A (Male) and 1B (Female)\] received a sodium chloride solution (0.9 % w/v) for 14 days.ii.**Treatment group** \[2A (Male) and 2B (Female)\] received SA (1000 mg/kg/day, p.o) for 14 days.iii.**Satellite group** \[3A (Male) and 3B (Female)\] received SA (1000 mg/kg/day, p.o for 14 days) and observed for another 14 days post treatment.

All the animals have been observed for mortality on daily basis and in-life clinical signs, body weight, food and water intake were recorded on weekly basis. The control group and treatment group animals were sacrificed on day 15 for required evaluations as per the experimental design.

In order to access reversibility or recovery; satellite group was continued for another 14 days post-treatment. All the rats were observed on daily basis for mortality. In-life clinical signs, body weight, food and water intake were measured for additional day 21 and 28. On day 29 rats were sacrificed for endpoint evaluations ([@bib33]; [@bib40]; [@bib30]; [@bib9]).The schematic illustration of experimental design is shown in [Fig. 1](#fig1){ref-type="fig"}.Fig. 1The schematic illustration of experimental design.Fig. 1

2.6. In-life clinical observations {#sec2.6}
----------------------------------

Animals were observed twice a day for mortality. Observations of clinical signs were recorded during handling and in open field on day 0,7,14 for animals of the control and treatment group. Animals of satellite group were observed on additional day 21 and 28. Clinical signs included changes in sensory organs (such as skin, eyes, nose), body secretion, autonomic activities (respiratory rate, pupil size, piloerections), response while handling, walking pattern, overall body language, muscle tremor and behavior, etc. ([@bib41]).

2.7. Body weight and body weight gain {#sec2.7}
-------------------------------------

Animals were weighed twice prior to grouping. Body weights were recorded on days 1 (prior to dosing), 7, 14 and 15 (fasting body weight prior to sacrifice to calculate relative body organ weight) in treatment and control groups. Body weight measurements of animals of satellite group were continued on a weekly interval on day 21, 28 and 29 (prior to sacrifice) ([@bib33]; [@bib40]). At the end of the testing period, mean body weight gains were calculated for each group.

2.8. Food and water consumption {#sec2.8}
-------------------------------

Animals were allowed ad libitum access to food and water throughout the study. Food and water consumption for animals of treatment and control groups were measured on Days 1 (prior to dosing), 7 and 14. Measurements were continued for animals of satellite group for day 21 and 28 ([@bib21]; [@bib33]). Animals were fasted overnight prior to termination of the study.

2.9. Hematological analysis {#sec2.9}
---------------------------

At the termination of the study, all surviving animals were anesthetized by isoflurane and blood samples were collected via the inferior vena cava in pre-calibrated tubes coated with ethylene diamine tetraacetic acid (EDTA) for hematological assessment which was conducted by Unique Biodiagnostics Enterprises (Mumbai, India). The parameters are as follows: Red blood cells count (RBC), hemoglobin concentration (HBG), platelet count (PLT), packed cell volume (PCV), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), total white blood cell (TWBC), mean corpuscular hemoglobin concentration (MCHC) and differential leukocyte count, which includes percentage of neutorophill (N%), eosinophill (E%), lymphocytes (L%) and monocytes (M%).

2.10. Serum biochemistry {#sec2.10}
------------------------

The non-heparinized blood samples were collected for biochemical estimations. The coagulated blood samples were centrifuged at 2000 g to obtain serum. The serum was taken into new tubes and stored at -20 °C until analyzed. The serum biochemical parameters were estimated spectrophotometerically by using kits of analytical grade. Parameters include blood glucose (BG), blood urea nitrogen (BUN), creatnine (CR), total protein (TP), albumin (ALB), total billirubin (TB), direct billirubin (DB), Aspartate transaminase (AST), Alanine transaminase (ALT), alkaline phosphatase (ALP), calcium (Ca), sodium (Na), potassium (K), and chlorine (Cl), phosphate (P), lactate dehydrogenase (LDH), high density lipoprotein (HDL), triglyceride (TG) and total cholesterol (TC).

2.11. Gross necropsy and relative organ weight {#sec2.11}
----------------------------------------------

At scheduled terminal sacrifice (Day 15 and 29), all surviving animals were anesthetized and dissected out. A gross necropsy examination was performed to identify the presence of lesions which included examinations of the external surface of the body, all orifices, skeletal systems and body cavities (such as cranial, thoracic, abdominal, and pelvic) ([@bib21]). Immediately the lungs, liver, heart, spleen, kidneys, adrenal gland, testis/ovaries were excised, freed of fat, washed in cold saline, blotted with clean tissue paper, and observed for gross pathological changes. Then the organ weights were recorded in grams using a calibrated balance and relative body weights were calculated by taking ratio of these organ weights to body weight.

2.12. Histopathological examinations {#sec2.12}
------------------------------------

Samples of the liver, heart, kidneys, pancreas, hippocampus, sciatic nerve were collected for histological studies. The tissues were fixed immediately in 10% formalin, dehydrated through a series of ethanol solutions, and embedded in paraffin. Thin sections of 4-5-μm-thickness were cut with the help of rotary microtome and were stained with hematoxylin and eosin for photomicroscopic observation. All histopathological changes were examined by a pathologist. The microscopic features of the organs of both treated and satellite groups were then compared with those of the control group. Slide preparation and histological assessment were carried out by Unique Biodiagnostic Enterprises (Mumbai, India).

2.13. Statistical analysis {#sec2.13}
--------------------------

Data analysis was performed using GraphPad Instat 3.0 version (GraphPad, San Diego, CA). Data were expressed as mean ± standard deviation (SD) and analyze using one-way analysis of variance (ANOVA), Dunnett\'s multiple range test was applied for post hoc analysis. A value of P \< 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

3.1. Limit test {#sec3.1}
---------------

A single dose of 2000 mg/kg/p.o of SA did not show any mortality and signs of toxic effects in all 5 rats. Therefore, it can be concluded that the LD50 value may be greater than 2000 mg/kg. Hence, 1000 mg/kg dose was considered to be safe and by referring the published literature and OECD TG 407 ([@bib34]), this dose was selected to conduct a subacute toxicity study ([@bib33]; [@bib40]; [@bib30]).

3.2. In-life clinical observations {#sec3.2}
----------------------------------

All animals were observed daily for mortality. Observations for any clinical signs during handling and in the open field were recorded on a weekly basis till the termination of the study. No mortality was observed during and at the end of the study period in any of the animal groups. The experimental rats were observed critically during handling and in open field; no prominent clinical signs such as vocalization, lacrimation, salivation, irregular respiratory pattern, convulsion, tremors and no unusual behavior were observed in the animals of treatment group and satellite group as compared to control group. The details are summarized in Table S1 (Provided in supplementary material).

3.3. Body and relative organ weight {#sec3.3}
-----------------------------------

Changes in the body weights were summarized in [Fig. 2](#fig2){ref-type="fig"}. It was recorded on a weekly basis. Proper increase in body weights were found in animals of treatment and satellite group as compared to normal control animals.Fig. 2Body weight gain of rats in subacute toxicity studies of the SA. Values are expressed as mean ± SD (n = 6), \*p \< 0.05, \*\*p \< 0.01 compared to control group with statistical analysis by one-way ANOVA followed by Dunnett\'s post-hoc test. SA^t^ is a group of animals treated with syringic acid (1000 mg/kg) for 14 days and then sacrificed. SA^s^ is a satellite group treated with syringic acid (1000 mg/kg) for 14 days, no treatment for another 14 days and then sacrificed.Fig. 2

3.4. Food and water consumption {#sec3.4}
-------------------------------

Food consumption for the treatment and satellite groups of male and female animals were compared with vehicle-treated control group. During the study, the proper increase in food consumption was observed in male animals of treatment and satellite groups. However, decreased food consumption on Day 7 in female treatment group was observed, followed by a proper increase on day 14 ([Fig. 3](#fig3){ref-type="fig"}), the female animals of satellite group showed a regular increase in food consumption. However, this initial decreased food consumption did not result in an overall decrease in body weights of female rats and hence are not interpreted to be toxicologically relevant. Further, oral administration of SA caused no major alteration in water consumption in the treatment and satellite groups compared to control group.Fig. 3Food consumption of rats administered daily doses of SA. Values are expressed as mean ± SD (n = 6), \*p \< 0.05, \*\*p \< 0.01 compared to control group with statistical analysis by one-way ANOVA followed by Dunnett\'s post-hoc test. SA^t^ is a group of animals treated with syringic acid (1000 mg/kg) for 14 days and then sacrificed. SA^s^ is a satellite group treated with syringic acid (1000 mg/kg) for 14 days, no treatment for another 14 days and then sacrificed.Fig. 3

3.5. Hematological examination {#sec3.5}
------------------------------

The results of hematological examination were presented in [Table 1](#tbl1){ref-type="table"}.Table 1Effect of SA on hematological parameters at the termination of study.Table 1ParametersGroups (Male)Groups (Female)ControlSA^t^SA^s^ControlSA^t^SA^s^Hb (gm%)13.00 ± 0.4412.68 ± 0.9515.33 ± 0.82\*\*12.35 ± 0.8012.10 ± 1.5214.18 ± 0.82\*RBC (x 10^6^/cmm)07.34 ± 0.2307.32 ± 0.6208.98 ± 0.37\*\*06.89 ± 0.4006.51 ± 0.7607.97 ± 0.65\*WBC (x 10^3^/cmm)11.88 ± 3.7413.88 ± 1.8811.51 ± 2.0310.13 ± 2.9110.63 ± 3.5410.23 ± 2.94PLT(x 10^5^/cmm)09.48 ± 1.2008.47 ± 1.3610.49 ± 1.2208.87 ± 1.7909.14 ± 1.9009.11 ± 1.17PCV (%)33.86 ± 1.2934.75 ± 2.4049.33 ± 2.76\*\*32.73 ± 1.9032.40 ± 3.7046.25 ± 2.43\*\*MCV(fl)46.06 ± 0.5647.85 ± 1.40\*54.56 ± 1.39\*\*47.58 ± 0.7549.85 ± 1.5858.2 ± 2.31\*\*MCH (pg)17.61 ± 0.2317.28 ± 0.2617.00 ± 0.23\*\*17.88 ± 0.3318.50 ± 0.27\*17.76 ± 0.54MCHC (gm/dl)38.33 ± 0.4236.21 ± 0.84\*\*30.95 ± 0.18\*\*37.66 ± 0.7537.26 ± 1.0030.61 ± 0.34\*\*WBC (x 10^3^/cmm)11.88 ± 3.7413.88 ± 1.8811.51 ± 2.0310.13 ± 2.9110.63 ± 3.5410.23 ± 2.94N %44.66 ± 8.8054.16 ± 4.02\*64.66 ± 6.50\*\*44.00 ± 17.2946.33 ± 12.8660.66 ± 4.54E %02.83 ± 2.8507.16 ± 6.360.83 ± 0.7506.00 ± 4.6003.00 ± 3.221.16 ± 1.16\*L %51.00 ± 9.7137.83 ± 9.80\*34.00 ± 6.98\*\*49.33 ± 21.2249.50 ± 15.2437.33 ± 4.59M %01.5 ± 1.760.83 ± 0.400.50 ± 0.540.66 ± 0.511.16 ± 0.750.83 ± 0.75[^1][^2]

The Male treatment group of rats showed no significant increase in the HGB, RBC, PCV, PLT, MCH except increased MCV (p \< 0.05) and MCHC level (p \< 0.01). In female treatment group no significant changes in hematological parameters were found except an increase in MCH (p \< 0.05). All hematological parameters were found to be increased (p \< 0.01) but within normal range in male and female satellite groups.

In male treatment group there was a similar WBC count when compared to a normal control group but, increase in neutrophills (p \< 0.05) and decrease in lymphocyte count (p \< 0.05) were observed with no recovery in satellite group. No significant change in WBC count was observed in female animals of treatment and satellite group, but a significant decrease in eosinophill count (p \< 0.05) was observed in satellite group.

3.6. Blood biochemistry {#sec3.6}
-----------------------

The data of blood biochemistry represented in [Table 2](#tbl2){ref-type="table"}, biochemical analysis involved estimations such as BG, BUN, CR, TP, albumin, TB, DB, AST, ALT, ALP, electrolytes (Ca, K, Cl and P), LDH, lipid profile \[HDL, TC and TG\].Table 2Effect of SA on biochemical estimations in Wistar rats.Table 2ParametersGroups (Male)Groups (Female)ControlSA^t^SA^s^ControlSA^t^SA^s^BG (mg/dl)89.26 ± 10.4279.23 ± 11.6091.92 ± 8.8298.23 ± 13.7591.73 ± 8.1993.42 ± 10.09BUN (mg/dl)20.24 ± 1.9419.70 + 1.8821.12 ± 0.9722.07 ± 11.6723.34 ± 1.7221.41 ± 1.26CR (mg/dl)0.51 ± 0.040.47 ± 0.070.50 ± 0.040.49 ± 0.100.52 ± 0.050.53 ± 0.06TP (g/dl)6.48 ± 0.766.66 ± 0.827.02 ± 0.387.37 ± 0.487.45 ± 0.347.30 ± 0.40ALB (g/dl)4.97 ± 0.234.83 ± 0.345.04 ± 0.434.99 ± 0.395.08 ± 0.285.09 ± 0.22TB (mg/dl)0.21 ± 0.030.23 ± 0.050.22 ± 0.030.24 ± 0.040.23 ± 0.030.22 ± 0.03DB (mg/dl)0.062 ± 0.010.04 ± 0.020.06 ± 0.0270.081 ± 0.050.08 ± 0.060.102 ± 0.05AST (U/L)84.32 ± 7.3287.02 ± 5.2786.07 ± 4.4073.08 ± 9.2976.62 ± 6.3371.37 ± 5.93ALT (U/L)32.81 ± 3.7331.71 ± 3.7331.42 ± 3.1228.80 ± 3.9431.71 ± 3.3830.55 ± 3.50ALP (U/L)262.48 ± 6.69246.16 ± 14.87266.56 ± 32.91152.77 ± 12.80126.48 ± 10.70\*\*151.86 ± 11.97Ca (mg/dl)11.21 ± 0.7810.09 ± 1.1910.43 ± 0.7711.38 ± 1.0211.01 ± 0.5710.44 ± 0.66K (mEq/L)7.54 ± 1.898.00 ± 0.688.54 ± 1.278.75 ± 0.858.75 ± 1.007.87 ± 1.67Cl (mEq/L)103.76 ± 5.69105.44 ± 12.77112.2 ± 12.50106.77 ± 7.27108.87 ± 9.67110.73 ± 10.70Na **(**mEq/L)86.03 ± 4.9086.78 ± 27.8481.00 ± 22.5182.33 ± 15.4664.33 ± 21.7768.59 ± 9.74P (mg/dl)5.93 ± 1.875.83 ± 1.506.14 ± 1.606.11 ± 0.736.65 ± 1.526.68 ± 1.59LDH (U/L)361.44 ± 82.50361.44 ± 82.50356.93 ± 48.51473.90 ± 117.43365.68 ± 48.99403.90 ± 40.26HDL (mg/dl)20.00 ± 3.5321.25 ± 4.1021.66 ± 5.7921.66 ± 4.3722.50 ± 5.4724.58 ± 4.30TCl (mg/dl)81.44 ± 7.9287.18 ± 5.7383.41 ± 8.2887.96 ± 4.1488.45 ± 3.7887.98 ± 6.15TG (mg/dl)110.66 ± 6.22105.21 ± 5.73108.08 ± 5.48108.37 ± 8.08114.26 + 7.74110.65 ± 10.86[^3][^4][^5]

All biochemical parameters were found to be unaltered in male and female treatment and satellite groups when compared to the respective normal control group except ALP level (p \< 0.01) in female treatment group was decreased significantly which was found recovered in satellite group.

3.7. Gross necropsy and relative organ weight {#sec3.7}
---------------------------------------------

Macroscopic examination includes critical observation of body systems and/or organs such as gastrointestinal systems (stomach, duodenum, jejunum, ileum, cecum, colon and rectum), lungs, brain, pancreas, sciatic nerve, skeletal muscles, kidneys, adrenal gland, reproductive organs (testis or ovaries), heart, liver, spleen, all orifices and body cavities. Macroscopic findings showed no irregularities in gross anatomical features of organs of male and female treatment groups as compared to control group animals. Satellite group too showed no major alterations in structure of organs.

No significant decrease in relative body organ weights was observed in male treatment group but a significant increase in relative weight of heart and spleen was reported in respective satellite group. In female treatment group, a significant decrease in liver weight was observed and it was not recovered in satellite group. Other internal vital body organs had no major alteration in weight in female rats.

3.8. Histopathological findings {#sec3.8}
-------------------------------

The 6 organs were used for histopathological findings in the current study. As shown in [Fig. 4](#fig4){ref-type="fig"}, no pathological changes were observed in treatment and satellite groups as compared to normal control animals.Fig. 4Histological results of vital internal body organs after oral administration of SA. SA^t^ is a group of animals treated with syringic acid (1000 mg/kg) for 14 days. SA^s^ is a satellite group treated with syringic acid (1000 mg/kg) for 14 days, no treatment for another 14 days.Fig. 4

The detail analyses are as follows:

Hypothalamus: Sections revealed normal neuronal histomorphological features with intact supporting matrix.

Heart: Section of heart tissues showed normal features of cardiac muscle fibers, cardiac fibers were arranged in dense and compact fashion with intact length and normal cell striation and nuclei.

Kidney: Examination of kidney tissue sections showed normal glomeruli and renal tubules in the cortex and medulla.

Liver: The tissue sections showed intact hepatic parenchyma comprised of hepatocytes, portal triad and central vein. Hepatocytes were arranged in cords with intact nucleus and cellular borders.

Sciatic nerve: The tissue sections showed normal histomorphological features of nerve tissue with an intact length of nerve fiber and normal cellular detail.

Pancreas: Sections showed normal appearance of the islets of Langerhans.

No inflammatory or metabolic changes were observed in all histological sections of vital body organs.

4. Discussion {#sec4}
=============

SA is a potent antioxidant and investigated for diverse pharmacological effects ([@bib31]; [@bib16]; [@bib4]; [@bib38]; [@bib22]; [@bib26]; [@bib35]; [@bib1]; [@bib17]; [@bib31]; [@bib7]). To achieve optimum therapeutic benefits one has to take it for long duration and hence toxic or undesirable effects cannot be ignored. In the current literature no systematic information on toxicity is available. Therefore, it was decided to conduct a subacute toxicity study, the research finding will not only add value to its ethanopharmacological profile, but also provides information on possible health hazards likely to arise from repeated administration over a limited period of time ([@bib15]). In addition, the study will help to establish doses for the longer-term subchronic studies ([@bib9]). The study was planned (shown in [Fig. 1](#fig1){ref-type="fig"}) as per the OECD TG407 ([@bib34]) and previous reported studies ([@bib33]; [@bib40]; [@bib30]; [@bib9]). To select the dose of SA for subacute toxicity study; a limit test was performed by using a single dose (2000 mg/kg p.o) ([@bib12]). Rats were observed critically for any toxic effect and mortality. No toxic symptoms and mortality were observed during and at the end of 14 days. Generally the toxic effect of drugs caused toxic signs and/or mortality. Therefore, this result showed that LD50 value of SA may be greater than 2000 mg/kg and 1000 mg/kg dose of SA may be safe for subacute toxicity study.

Toxic signs, food and water intake, if taken together, may indicate malaise or covert toxicity long before overt signs; if the animal does not feel well it will not eat sufficient food and/or drink the usual amount of water. Hence, body weight, food and water intake are the indicator of general health. Therefore, these parameters are crucial to assess the safety of the drug during the subacute toxicity study ([@bib37]; [@bib33]). Figs. [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} showed the effect of SA on body weight and food intake. Proper increase in body weight was reported along with normal increase in food and water intake compared with control group animals. In-life clinical observations were recorded during the study and the animals of treated and satellite groups didn\'t show any toxic symptoms, it could be concluded that oral administration of SA during subacute toxicity study period has no undesirable effect on the growth and physiological functions of rats.

Biochemical and hematological evaluations were amongst important parameters to assess safety of drug ([@bib37]; [@bib25]; [@bib8]) therefore, they were estimated in current subacute toxicity study. Male treatment group of rats showed no significant increase in the HGB, RBC count, PCV, PLT count, MCH except MCV and MCHC with no recovery in the satellite group ([Table 1](#tbl1){ref-type="table"}). All hematological parameters were found to be increased in satellite group, but within the normal range which cannot be considered as a toxic effect ([@bib19]). This can be justified by taking into consideration, a condition of decrease in HBG, RBC count and other related parameters which showed anemic effect and adverse effect of SA on erythropoiesis. Total WBC count in male treatment group showed no increase as compared to normal control group, but increase in neutrophil and decrease in lymphocyte count was observed with no recovery in satellite group, this effect may justify antibacterial ([@bib4]) and anti-inflammatory effect ([@bib17]) of SA. No significant change in WBC count was observed in female treatment and satellite group except eosinopenia in satellite group, but still it corroborate wide safety of SA ([@bib2]). Hence, the results endorsed non toxicity of SA on physiology of red bone marrow.

Effect of SA on biochemical parameters were presented in [Table 2](#tbl2){ref-type="table"}. DB, AST, ALT and ALB levels are index of liver function ([@bib23]). No significant changes were reported in the treatment group and satellite group as compared to normal control group. In addition, histopathological reports showed no major alteration in the structural features of the liver. Hence, SA could not be considered toxic to the liver and this fact is supported by the non-significant change in BG and CR levels in the treated group as compared to normal control ([@bib3]). ALP is a group of enzymes which catalyze the hydrolysis of phosphate esters generating organic radicals and inorganic phosphate ([@bib32]). In the present study, low level of ALP in treated group with no recovery in the satellite group of female rats was reported, the low ALP level is an indicator of Wilson disease also known as hepatolenticular degeneration associated with pernicious anemia, hypophosphatasia and hypercupremia ([@bib10]) but the same situation was not observed in male treatment group and not supported by histopathological studies of liver, non-significant change in serum ALT, AST, DB and phosphate level and no reduced RBC count. Therefore, it may not be considered as a severe toxic effect.

BUN, CR, TP and LDH are indicators of renal function ([@bib39]; [@bib5]). No statistically significant change was reported in the treatment and satellite groups of rats. These observations revealed that oral administration of SA may not affect the anatomical features of kidney, which is supported by the normal structural features found in histopathological studies and no significant change in relative kidney weight in the treatment and satellite group of both male and female rats. Therefore, administration of SA during the subacute study period might be safe for kidneys.

Electrolyte balance is an indicator of osmotic regulation by blood, kidney and cardiac function, digestion and intermediary metabolism ([@bib29]; [@bib28]). Serum electrolytes (Na, K, Ca and P) levels were estimated at the end of the study period ([@bib36]; [@bib24]). No significant changes were observed in treatment and satellite groups as compared to control group. This observation showed that the SA is not affecting the digestive system, metabolism process, cardiac and renal functioning which is further supported by the non significant changes in renal, lipid parameters (TG, HDL and TC) and normal histological finding of heart and liver. Hence it could be concluded that SA may not have any adverse effect on electrolyte balance.

Observation of relative internal body organ weight is a crucial parameter to assess safety of drug ([@bib37]; [@bib33]). The relative organ weights were found unaltered in male treatment group, however an increased heart and spleen weight were observed in respective satellite group ([Table 3](#tbl3){ref-type="table"}). This may not be considered as a toxic effect and can be linked with body weight changes ([@bib7]). In female treatment group, a significant decrease in relative liver weight was observed with no recovery in satellite group, but it is not consistent with observation of male groups, not in coordination with the results of histopathological study and estimation of liver enzymes. It may an adaptive change and non adverse change, hence may not be considered as a toxic effect ([@bib14]). There were no major alterations in relative weight for other organs in both the male and female rats. Toxic effect of SA on internal vital organ was further verified with the help of histopathological studies which showed no abnormalities. Therefore, it could be concluded that SA might not have major toxic effects on internal vital body organs.Table 3Effect of SA on relative body organ weight of Wistar rats.Table 3Organ weight (g % body weight)Groups (Male)Groups (Female)OrgansControlSA^t^SA^s^ControlSA^t^SA^s^Lung0.47 + 0.010.43 + 0.010.45 + 0.100.49 + 0.0010.51 + 0.020.51 + 0.02Heart0.37 + 0.010.36 + 0.020.40 + 0.02\*0.31 + 0.020.28 + 0.020.29 + 0.03Liver3.71 + 0.043.64 + 0.163.76 + 0.062.92 + 0.112.70 + 0.09\*2.62 + 0.03\*Spleen0.37 + 0.010.35 + 0.030.42 + 0.03\*\*0.25 + 0.010.24 + 0.020.26 + 0.02Kidney0.47 + 0.010.46 + 0.010.48 + 0.0050.46 + 0.070.41 + 0.020.48 + 0.09Testis/Ovary0.63 + 0.020.61 + 0.020.62 + 0.010.11 + 0.010.10 + 0.010.10 + 0.008Adrenal gland0.017 + 0.0010.016 + 0.0010.016 + 0.0010.016 + 0.0010.014 + 0.0030.017 + 0.003[^6][^7][^8]

5. Conclusion {#sec5}
=============

SA is a polyphenol with diverse pharmacological effects. Recent reports showed that safety is a major concern for phytochemicals too. No systematic study is available on subacute toxicity of SA. Therefore, it was decided to conduct a subacute study, which will be considered preliminary to subchronic and chronic studies. The results of physical, hematological and biochemical parameters during and at the end of the subacute toxicity study had shown no significant changes in SA treated rats. Thus the process of erythropoiesis, leukopoiesis and physiology of internal body organ were not disturbed. No structural abnormalities were observed in histopathological studies. Hence, SA could be considered safe over limited period of time and this study may help researcher in establishing doses for the longer-term subchronic studies. Further, subchronic and chronic toxicity studies are required to evaluate safety on long term use.
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[^1]: Values are expressed as mean ± SD (n = 6), \*p \< 0.05, \*\*p \< 0.01 compared to control group with statistical analysis by one-way ANOVA followed by Dunnett\'s post-hoc test.

[^2]: **SA**^**t**^ is a group of animals treated with syringic acid (1000 mg/kg) for 14 days and then sacrificed. **SA**^**s**^ is a satellite group treated with syringic acid (1000 mg/kg) for 14 days, no treatment for another 14 days and then sacrificed.

[^3]: Values are expressed as mean ± SD (n = 6), \*p \< 0.05, \*\*p \< 0.01 compared to control group with statistical analysis by one-way ANOVA followed by Dunnett\'s post-hoc test.

[^4]: **SA**^**t**^ is a group of animals treated with syringic acid (1000 mg/kg) for 14 days and then sacrificed.

[^5]: **SA**^**s**^ is a satellite group treated with syringic acid (1000 mg/kg) for 14 days, no treatment for another 14 days and then sacrificed.

[^6]: Values are expressed as mean ± SD (n = 6), \*p \< 0.05, \*\*p \< 0.01 compared to control group with statistical analysis by one-way ANOVA followed by Dunnett\'s post-hoc test.

[^7]: **SA**^**t**^ is a group of animals treated with syringic acid (1000 mg/kg) for 14 days and then sacrificed.

[^8]: **SA**^**s**^ is a satellite group treated with syringic acid (1000 mg/kg) for 14 days, no treatment for another 14 days and then sacrificed.
